Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility

被引:69
作者
Papanikolaou, A [1 ]
Wang, QS [1 ]
Delker, DA [1 ]
Rosenberg, DW [1 ]
机构
[1] Univ Connecticut, Dept Pharmaceut Sci, Mol Toxicol Lab, Sch Pharm, Storrs, CT 06269 USA
关键词
aberrant crypt foci; azoxymethane; colon carcinogenesis; tumor susceptibility; inbred mice;
D O I
10.1016/S0304-3835(98)00101-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Azoxymethane (AOM) is an organotropic colon carcinogen that is commonly used to induce colon tumors in rodents. Unlike its parent compound, 1,2-dimethylhydrazine (DMH), a tumor susceptibility phenotype in inbred mice with respect to AOM has not been established. Thus, this study was undertaken to determine whether genetic susceptibility extends to this carcinogen. SWR/J, A/J (both susceptible to DMH carcinogenesis) and AKR/J (resistant) mice were treated with 10 mg/kg AOM i.p. once a week for 8 weeks. Twenty-five weeks after the initial injection, tumor yield was determined. With a single exception, only SWR/J and A/J mice developed tumors, with a distribution that was limited to the distal colon (16.3 +/- 1.1 and 36.4 +/- 2.4, respectively). The formation of aberrant crypt foci (ACF), putative preneoplastic lesions, was also assessed in whole-mount colons using Methylene Blue staining. Consistent with tumor multiplicity, the total number of ACF was highest in A/J mice, followed by SWR/J mice. In addition, A/J mice had a significantly greater number of large ACF (five or more crypts per foci) than the other strains. Despite the absence of colon tumors, however, AKR/J mice did develop a significant number of ACF. This finding suggests that ACF in resistant mice are persistent but do not progress to tumors. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 18 条
[1]   OBSERVATION AND QUANTIFICATION OF ABERRANT CRYPTS IN THE MURINE COLON TREATED WITH A COLON CARCINOGEN - PRELIMINARY FINDINGS [J].
BIRD, RP .
CANCER LETTERS, 1987, 37 (02) :147-151
[2]  
Delker DA, 1996, DRUG METAB DISPOS, V24, P408
[3]  
DELKER DA, 1997, P AM ASSOC CANC RES, V38, P2376
[4]  
DESCHNER EE, 1988, CANCER, V61, P478, DOI 10.1002/1097-0142(19880201)61:3<478::AID-CNCR2820610312>3.0.CO
[5]  
2-A
[6]  
DIWAN BA, 1977, J NATL CANCER I, V59, P455, DOI 10.1093/jnci/59.2.455
[7]  
DIWAN BA, 1979, P SOC EXP BIOL MED, V161, P347
[8]  
DRUCKREY E, 1970, CARCINOMA COLON ANTE, P267
[9]  
EVANS JT, 1977, CANCER RES, V37, P134
[10]   DIFFERENTIAL SUSCEPTIBILITY OF 4 MOUSE STRAINS TO INDUCTION OF MULTIPLE LARGE-BOWEL NEOPLASMS BY 1,2-DIMETHYLHYDRAZINE [J].
EVANS, JT ;
HAUSCHKA, TS ;
MITTELMAN, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 52 (03) :999-1000